ture, vascular insult and autoimmune inner ear disease have been proposed to be potential causal factors. The spontaneous recovery in untreated patients characteristically arises within two weeks in 45% to 65% of cases. [2] Even though spontaneous recovery might develop in some cases, numerous therapeutic regimens including corticosteroids, vasodilators, antiviral drugs, plasma expanders, carbogen and hyperbaric oxygen have been used due to the multifactorial etiopathology of ISSNHL. Among them, systemic steroids are widely used as a standard therapy. [3] However, no matter which procedure is chosen, the hearing outcome is limited. Approximately half of the patients have a poor response to oral or intravenous steroid therapy, and only 61% achieve complete recovery. [4] Therefore, salvage therapy has been common recently for these cases who are refractory to steroid therapy. A current clinical guideline has recommended the use of intratympanic steroid (ITS) when cases have partial recovery after failure of initial treatment. [5] Besides, ITS can be used as combination therapy (ITS+ systemic steroid tapering) for initial management. Recently, data from three randomized controlled studies showed the benefit of combination therapy, especially in patients with mild-to-severe hearing loss. [6] [7] [8] In our institution, we have been preferring combination therapy as the initial management for ISSNHL and HBO therapy as salvage or adjuvant therapy after failure of combination therapy since 2013.
Hyperbaric oxygen therapy is used as primary or salvage therapy for ISSNHL. However, the efficacy of salvage HBO therapy is still unclear and varies among studies. The purpose of this study was to determine whether HBO therapy is beneficial as a salvage therapy for ISSNHL after failure of initial combination steroid therapy or not.
Materials and Methods

Patients
The medical records of patients who were treated with salvage HBO therapy for ISSNHL after failure of combination therapy between June 2013 and June 2017 in a tertiary care center were reviewed retrospectively. The Institutional Review Board approved this study (23-February 05, 2015). A total of 48 patients who met the following criteria were included: (1) unilateral ISSNHL which was defined as a hearing loss of ≥30 dB in at least 3 contiguous frequencies over a period of ≤3 days; (2) the cause of hearing loss was unknown; (3) time from the onset of hearing loss to the treatment ≤14 days; (4) no fluctuation in hearing loss; (5) no history of ear disease in the affected ear; (6) received salvage HBO therapy. Patients who did not complete the full course HBO therapy were excluded from the study.
Treatment characteristics
All the patients were hospitalized and treated with a 14-day course of oral steroid (1 mg/kg of oral methylprednisolone and 10 mg tapering for 3 days). Patients were also given proton pump inhibitors for gastrointestinal protection. ITA was also applied during this 14 day course of oral steroid as adjunctive therapy (administration of 0.4 mL of 62.5 mg/mL methylprednisolone once every three days). Patients were referred to HBO therapy after initial therapy if they had failed primary therapy or showed slight recovery.
HBO therapy was performed in a hyperbaric chamber where they breathed 100% oxygen at 2.5 atmospheres pressure for 60 minutes once daily (a total of 20 sessions).
Evaluation criteria
All patients underwent audiometry just before and 1 month after the HBO therapy. Hearing thresholds at 250, 500, 1000, 2000, 4000 and 8000 Hz were noted. Pure tone average (PTA) calculated as an average of the threshold was measured at 0.5, 1, 2 and 4 kHz. 
Statistical analysis
All continuous variables were expressed as mean±standard deviation, and categorical variables were expressed as percentage. The data normality test to evaluate the distribution of variables was done with the Kolmogorov-Smirnov test. Paired t test was used for continuous variables with normal distribution, and Mann-Whitney U test was used for continuous variables without normal distribution. The relationship between independent variables (age, gender, initial PTA, PTA before HBO, presence of vertigo, tinnitus and comorbid disease, and neutrophil/lymphocyte ratio) and the clinical outcome after HBO therapy were assessed using chisquare, Fisher's exact and Mann-Whitney U tests. After HBO therapy, significant improvement was found in mean hearing thresholds at all frequencies. Mean hearing levels before and after HBO therapy are shown in Fig. 1 .
Hearing improvement was independent of age, days from onset to treatment, audiogram type, neutrophil/lymphocyte ratio, and presence of vertigo, tinnitus and comorbid disease. Only the initial PTA level and gender were significantly associated with recovery. We analyzed the hearing improvement in patients according to the level of initial PTA. Patients were divided in those with severe hearing loss (≥70 dB) and those with moderate hearing loss (<70 dB). Patients with ≥70 dB initial level of PTA showed statistically significant hearing improvement after HBO therapy while patients with <70 dB initial level of PTA did not have any improvement (p=0.022; Tables 2 and 3 is a linear-by-linear association with initial level of PTA and hearing recovery (p=0.027).
Discussion
In patients with ISSNHL who failed to recover after steroid therapy, both patient and clinician concern about what can be done else. The most commonly used salvage therapies are ITS and HBO therapy if they are not administered as primary treatment. ITS or HBO therapy applied either as salvage or adjuvant therapy for ISSNHL has shown positive results in terms of hearing improvements. [9] But there is still ongoing controversy about which salvage therapy is better. Furthermore, to the best of our knowledge, there is very limited data regarding the efficacy of HBO therapy following combined steroid (systemic+ITS) treatment. [10] In our study, we found that the addition of HBO therapy after failure of combined steroid treatment led to statistically significant hearing improvement in patients with severe (≥70 dB) hearing loss. HBO therapy showed significant improvement in mean hearing thresholds at all frequencies. The overall recovery rate, including complete recovery, partial recovery and slight recovery was 27%. But complete recovery is very rare (4%).
Perilymphatic oxygen tension decreases significantly in patients with ISSNHL. HBO therapy increase oxygen tension in blood and perilymphatic fluid. [11] A recent Cochrane review indicated a significantly greater chance of a 25% increase in the average PTA level in patients receiving HBO therapy. [12] Although prospective clinical trials of salvage HBO therapy with a control group are limited, result of these studies showed some benefits in hearing improvement. [10, 13, 14] The results of salvage HBO therapy in previous studies are demonstrated in Table  4 . [9, [14] [15] [16] [17] [18] To date, no reports have been published about the hearing outcomes of salvage HBO therapy after combined steroid treatment. The results of this study indicate that there is still something to do after combined steroid treatment in ISSNHL.
HBO therapy is used either as primary treatment or as salvage therapy in the management of ISSNHL. There is still no universally accepted approach. Similarly, ITS is performed for ISSNHL as salvage therapy or as primary therapy. Although the efficacy of steroids in ISSNHL is still conflicting irrespective of the delivery method, recent previous studies found that combined steroid treatment (systemic steroid+ITS) provides better hearing recovery than systemic steroid alone. [6, 7] Suzuki et al. reported that systemic plus intratympanic steroid administration is more effective than systemic steroid plus HBO therapy. [19] It is believed that the diffusion of higher steroid concentration into cochlear fluids reduces inflammation in the inner ear. Therefore, HBO and ITS may have synergistic role in decreasing edema in the cochlea. In the current study, salvage HBO therapy following systemic plus intratympanic steroid therapy provided additional improvement in patients with severe hearing loss.
Patient age, audiogram type, presence of vertigo and comorbid disease did not affect hearing recovery rates. However, interestingly, gender differences occurred in our study. Female patients showed better recovery rates than males. There is no supporting data in the literature for this condition, but it may be explained by the fact that there are differences in oxygen, nitrogen and carbon dioxide rates of loading and tissue gas tensions between males and females. [20] Prior reports have revealed the advantage of HBO treatment just among the cases with profound hearing loss (>60, >80 or >90). [5, 13] Similarly, we found that only patients with severe hearing loss (cut-off level of initial PTA was at 70 dB) had significant hearing improvement after HBO therapy. Previous studies on salvage HBO therapy reported mostly mean gains of hearing. However, although the improvement in terms of PTA is statistically significant, categorical recovery indicating the clinically improvement is important in these patients when interpreting the results. In our study, overall recovery rate was 27% (4% complete, 7% partial and 15% slight recovery, respectively).
The main limitation of our study is the relatively small sample size and retrospective design of the study without control group which is subject to the omissions and inaccuracies in the medical records. This study represents a single institutional experience. Nevertheless, although the results of our study have to be interpreted cautiously in the light of these preservations, we believe that this preliminary study presents an important data that may be used to design a larger prospective trial.
Conclusion
According to results of our study, salvage HBO therapy may be beneficial in patients with ISSNHL who failed to recover by primary combined steroid therapy. Further hearing recovery with salvage HBO therapy can be expected, particularly in patients with PTA greater than 70 dB.
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